Claims for Patent: 8,377,690

Summary for Patent: 8,377,690

Title:	Cells and methods for producing blocking antibodies to human RANKL
Abstract:	Described herein are cell lines and methods for preparing antibodies that bind RANKL, including cell lines that produce blocking antibodies to human RANKL.
Inventor(s):	Anderson; Dirk M (Port Townsend, WA)
Assignee:	Immunex Corporation (Thousand Oaks, CA)
Application Number:	12/802,801
Patent Claims:	1. A cell that produces a blocking antibody, wherein the blocking antibody binds to a human RANKL polypeptide as set forth in SEQ ID NO:13 and inhibits the binding of the human RANKL polypeptide to a human RANK polypeptide as set forth in SEQ ID NO:6. 2. A cell that produces a blocking antibody, wherein the blocking antibody binds to a fragment of a human RANKL polypeptide as set forth in SEQ ID NO:13 and inhibits the binding of the human RANKL polypeptide to a human RANK polypeptide as set forth in SEQ ID NO:6, wherein the fragment is selected from the group consisting of a) an extracellular domain comprising amino acids 69-317 of SEQ ID NO:13, and b) a receptor binding domain comprising amino acids 162-317 of SEQ ID NO:13. 3. A method of producing a blocking antibody, comprising culturing the cell of claim 1 under conditions that permit the production of the blocking antibody. 4. A method of producing a blocking antibody, comprising culturing the cell of claim 2 under conditions that permit the production of the blocking antibody.

Details for Patent 8,377,690

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Amgen Inc.	PROLIA	denosumab	Injection	125320	June 01, 2010		2016-12-23
Amgen Inc.	XGEVA	denosumab	Injection	125320	November 18, 2010		2016-12-23

International Patent Family for US Patent 8,377,690

Country	Patent Number	Estimated Expiration
Austria	E401404
Austria	E412746
Austria	E497001